MedTrace Logo

Biomarkers in Tissue Samples From Older Women With Breast Cancer

NCT01346579 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 505

Last updated 2016-07-04

No results posted yet for this study

Summary

This research trial studies phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) mutation analysis in tissue samples from older patients with stage I breast cancer. Studying samples of tissue from patients with stage I breast cancer in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer.

Conditions

Interventions

OTHER

laboratory biomarker analysis

Correlative sciences

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Alliance for Clinical Trials in Oncology

    lead OTHER

Principal Investigators

  • Mary Ellen Moynahan, MD · Memorial Sloan Kettering Cancer Center

Eligibility

Min Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2014-01-31
Completion
2014-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01346579 on ClinicalTrials.gov